# Mapping the neglected topic in head and neck paraganglioma research: a PRISMA scoping review on quality of life

**Authors:** Djenghiz P. S. Samlal, Marina Hristova, Angelika Albrecht, Joerg Schipper, Thijs T. G. Jansen, Corinne P. A. Delsing, Henricus P. M. Kunst

PMC · DOI: 10.1007/s11136-026-04218-8 · Quality of Life Research · 2026-03-13

## TL;DR

This review maps the impact of head and neck paraganglioma on patients' quality of life, highlighting gaps in understanding treatment effects.

## Contribution

The study is the first scoping review to systematically map HRQoL evidence in head and neck paraganglioma.

## Key findings

- HNPGL negatively affects HRQoL across multiple domains, even in non-intervention cases.
- Carotid body tumors, multiple tumors, and dysphonia are associated with lower HRQoL.
- Current evidence is limited, and more research is needed on treatment effects on HRQoL.

## Abstract

Paragangliomas in the head and neck (HNPGL) are rare slow growing neuro-endocrine tumors. The impact of various treatment strategies and tumor characteristics on health-related quality of life (HRQoL) remains unclear. This scoping review aims to map the available evidence and summarize the findings on how HNPGL affects patients’ HRQoL.

A comprehensive literature search was conducted in PubMed, Embase, and Cochrane. Articles were included when presenting a quantification of HRQoL or Patient Reported Outcome Measures in patients with HNPGL (n ≥ 5). Studies focusing exclusively on paragangliomas outside the head and neck region were excluded. A scoping review using descriptive and inductive thematic analysis was performed and presented using the Prisma-ScR guidelines.

Fourteen studies were included presenting quantifiable HRQoL data in patients with HNPGL. The most used HRQoL measure were the Short Form-36 (n = 4, 29%) and EORTC Core Quality of Life questionnaire (QLQ-C30) (n = 3, 21%), followed by Short Form-12 (n = 2, 14%). HNPGL negatively affects HRQoL across several domains, even in patients not requiring an intervention. Specific subgroups, including those with carotid body tumors, multiple tumors, or dysphonia, reported disproportionately lower HRQoL.

Current sparse evidence on HRQoL in patients with HNPGL demonstrates significant impairment and identified various factors influencing this outcome. However, further research is necessary to specifically assess the effect of different therapeutic managements on HRQoL.

The online version contains supplementary material available at 10.1007/s11136-026-04218-8.

## Linked entities

- **Diseases:** paraganglioma (MONDO:0000448), head and neck paraganglioma (MONDO:0006239)

## Full-text entities

- **Genes:** SDHB (succinate dehydrogenase complex iron sulfur subunit B) [NCBI Gene 6390] {aka CWS2, IP, MC2DN4, PGL4, PPGL4, SDH}
- **Diseases:** dyspnea (MESH:D004417), cranial nerve injury (MESH:D020209), Dysphonia (MESH:D055154), hearing handicap (MESH:D009422), cranial nerve deficit (MESH:D003389), hearing loss (MESH:D034381), and neck (MESH:D006258), Anxiety and Depression (MESH:D001007), headaches (MESH:D006261), vestibular Schwannoma (MESH:D009464), tinnitus (MESH:D014012), dysphagia (MESH:D003680), voice (MESH:D014832), vertigo (MESH:D014717), appetite loss (MESH:D001068), loss of HRQoL. (MESH:D000076082), bodily pain (MESH:D010146), CBT (MESH:D002345), pheochromocytomas (MESH:D010673), diarrhea (MESH:D003967), blood loss (MESH:D016063), nausea/vomiting (MESH:D020250), daytime sleepiness (MESH:D012893), Fatigue (MESH:D005221), sleep related problems (MESH:D020183), constipation (MESH:D003248), palpitations (MESH:D006331), neuro-endocrine tumors (MESH:D004701), Metastasis (MESH:D009362), Paraganglioma (MESH:D010235), depression (MESH:D003866), Cancer (MESH:D009369), impairment in physical mobility (MESH:D014086), panic attacks (MESH:D016584), malignant paraganglioma (MESH:C565335), residual hearing (MESH:D018365), apnea (MESH:D001049), , laryngeal (MESH:D007827), extra-adrenal paragangliomas (MESH:D010236), dizziness handicap (MESH:D004244), hypopnea (MESH:D012891), neuroendocrine tumors (MESH:D018358)
- **Chemicals:** catecholamines (MESH:D002395), proton (MESH:D011522)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12987911/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12987911/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12987911/full.md

---
Source: https://tomesphere.com/paper/PMC12987911